Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (CADEN)
|First Submitted Date ICMJE||August 4, 2009|
|First Posted Date ICMJE||August 6, 2009|
|Last Update Posted Date||August 18, 2017|
|Start Date ICMJE||November 2009|
|Primary Completion Date||June 2014 (Final data collection date for primary outcome measure)|
|Current Primary Outcome Measures ICMJE
||The primary endpoint of the study is to evaluate the overall response rate for patients with advanced-stage, relapsed/refractory, EBV positive nasopharyngeal carcinoma after re-induction chemotherapy and immunotherapy. [ Time Frame: 3 months ]
The overall response rate for patients with advanced-stage, relapsed/refractory, EBV positive nasopharyngeal carcinoma after re-induction chemotherapy (treatment with docetaxel and carboplatin) followed by immunotherapy with EBV-specific Cytotoxic T lymphocytes will be measured. Response rates will be estimated as the percent of patients whose best response is a CR or PR, and a 95% confidence interval will be calculated for the fraction of responses obtained.To measure the overall response rate, disease will be determined by imaging (MRI, CT, and/or PET imaging) 8 weeks after immunotherapy. In addition, per standard of care, disease re-evaluation will continue 3 months during the first year after participation and then as clinically indicated per the patient's primary oncologist.
|Original Primary Outcome Measures ICMJE
||To determine the overall response rate in patients with relapsed/refractory, advanced-stage, EBV positive NPC after tx with docetaxel and carboplatin followed by immunotherapy with EBV-specific cytotoxic T lymphocytes [ Time Frame: 3 months ]|
|Change History||Complete list of historical versions of study NCT00953420 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE
|Original Secondary Outcome Measures ICMJE
||To determine the response rate in patients treated with re-induction chemotherapy with carboplatin & docetaxel. To determine the expansion, persistence & anti-tumor effects given after re-induction chemotherapy with carboplatin & docetaxel. [ Time Frame: 1 year ]|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes|
|Official Title ICMJE||Phase II Study of Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes in Patients With Refractory/Relapsed EBV-positive Nasopharyngeal Carcinoma(CADEN)|
Patients have a type of cancer called nasopharyngeal carcinoma (NPC) that has either come back or not gone away after the best known standard treatments.
Most patients that respond to chemotherapy once their NPC tumors have come back have been treated with a platinum-based medication like cisplatin. However, since many patients are given cisplatin during their initial treatment for NPC, in this study, they will be treated with another platinum-based chemotherapy medicine that has been used in patients with NPC called carboplatin. In this study, carboplatin will be used in combination with another drug called docetaxel. Other studies in patients with advanced head and neck cancer have shown that docetaxel can cause tumors to respond better and allow patients to survive longer when added to the standard treatments for those diseases.
Some patients with NPC show evidence of infection with the virus that causes infectious mononucleosis, known as the Epstein Barr virus (EBV), before or at the time of their cancer diagnosis. EBV is found in the cancer cells of almost all patients with advanced stage disease, suggesting that it may play a role in causing NPC. Previously, patients have been treated with high-risk NPC using EBV-specific cytotoxic T cells. These cells are grown in the laboratory and taught to recognize and attack EBV infected cells. In the past, patients were either given the cells alone or just after they had received a medication to briefly lower their white blood cell count. In both cases, many patients had their tumors shrink and in some cases completely disappear after being treated with these EBV-specific cytotoxic T cells.
Investigators have now decided to look at how patients with NPC and their tumors respond to the treatment combination of chemotherapy and EBV-CTL. Patients are being asked to participate in this study since the NPC tumor is associated with EBV and has either come back or not responded to standard treatment. This combination of chemotherapy and EBV-CTLs is an investigational treatment not approved by the Food and Drug Administration.
The purpose of this study is to see how relapsed or refractory, EBV-associated NPC tumors respond when treated with carboplatin and docetaxel followed by EBV-CTL.
A blood sample will be obtained to start making the CTLs before the patient begins chemotherapy. The patients EBV-specific T cells will be grown while the patient is being treated with chemotherapy and given back to the patient after their chemotherapy is completed.
To prepare the CTLs, 60-70 cc of blood will be taken from the patient. The amount of blood collected depends on their size and weight, no more than 3 cc of blood per kg of body weight will be collected at any one time.
This blood will be used to grow an EBV-infected B-cell line and then a T-cell line. B cells and T cells are types of white blood cells that help fight infections in the body. After growing T cells in the laboratory, these cells will be stimulated with EBV infected B cells. The B cells have been treated with radiation so they cannot grow; however, they can provide the stimulation that will train the T cells to recognize and kill EBV infected cells.
The generation of EBV-CTL requires the use of a special cell line, called lymphoblastoid cell line, which will be made from the blood by infecting cells with EBV. Once the LCLs are made, the T cells will be repeatedly stimulate with the LCLs to make EBV-CTL.
The CTLs will then be tested to make sure they kill the EBV infected cells before they are given back to the patient. If the number of CTLs produced is low, investigators may need to obtain additional blood samples to make these cells.
Because the patients cells are being grown in the laboratory, blood will have to be taken to test for infectious viruses such as hepatitis and HIV and patients will also have to fill in a questionnaire that is given to standard blood donors.
EXPECTED LENGTH OF STUDY The chemotherapy treatment portion is planned as 4 cycles of chemotherapy given every 3 weeks. Up to an additional 2 cycles of chemotherapy may be given if the EBV-CTL product is not available after the initial 4 cycles.
If the patient has been able to complete at least 4 cycles of chemotherapy and the EBV-CTL are ready for infusion,then the cells will be given back to the patient. The infusion of the T cells will last about 1 to 5 minutes after the patient has been pretreated with one dose of Tylenol and Benadryl.
The patient will have another disease re-evaluation 8 weeks after the first EBV-CTL injection. Based upon the patient's response to the first infusion, the patient may receive extra doses of cells if they are available. These would be given every 1.5-3 months. If the patient has additional injections of cells, this will require an additional disease re-evaluation 8 weeks after each infusion.
To learn more about the way the EBV-CTLS are working and how long they last in the body, 10-60 mls of blood will be taken before and after each infusion. Up to 60 ml of blood will also be drawn before each cycle of chemotherapy that occurs at Week 1, Week 4, Week 7, Week 10 before the T cell infusion and then at Weeks 1, 2, 4, 6 and 8 weeks after infusion, and then again at the follow-up visits 5, 8, and 11-12 months after infusion. This blood will be used to look at the immune response to the patient's cancer. If the patient only has one EBV-CTL infusion, up to 108 teaspoons of blood will be drawn to allow for evaluation of his or her response to treatment; however, the total amount of blood collected on this study will depend on the total number of EBV-CTL infusions that the patient has.
The patient and his/her response to therapy will be followed for at least 1 year after treatment on this study ends.
STUDY TREATMENT While the cells are being grown, the patient will be started on chemotherapy in order to shrink the size and/or amount of his/her tumor.
The patient will be treated with a combination of docetaxel and carboplatin chemotherapy. The chemotherapy will be given outpatient over several hours. Docetaxel can cause the body to hold on to extra fluid (fluid retention). This side effect can be prevented in most people if they take a small steroid dose before and after docetaxel is given. Therefore, the night before and on the morning chemotherapy is to start, the patient will take a steroid called dexamethasone by mouth.
Once the patient gets to clinic, he/she will be given a dose of docetaxel and then a dose of carboplatin. Each of these medications will be given into the vein after an IV is placed or into the central line. The patient will then take the last dose of dexamethasone before going to bed that night. The patient will receive chemotherapy treatment once every 21 days as long as the patient's blood counts and laboratory tests have returned to an acceptable level. The patient will have a re-evaluation of his/her disease with imaging scans and laboratory tests after the second round of chemotherapy. If the patient's tumor has not gotten worse and/or has not had severe side effects from the chemotherapy, the patient will be treated with 2 to 4 additional rounds of chemotherapy while we are waiting for the EBV-CTLs to be finished.
The combination of chemotherapy agents used in this study might cause the patient's white blood cells to be low. If they are low for a long period of time or the patient develop a serious infection while they are low, her/she may be given an extra medication called Granulocyte colony-stimulating factor (GCSF). GCSF helps to stimulate the production of white blood cells. However, it is anticipated that most people on the study will not require GCSF.
Once the EBV-CTLs are ready and the patient has recovered from the last round of chemotherapy, the EBV-CTL infusion will be scheduled. The CTL infusion will take place at either Houston Methodist Hospital or Texas Children's Hospital. The CTL infusion takes about 1 to 5 minutes, but patients are typically monitored for up to 4 hours after the infusion to make sure that he/she does not have a reaction to the cells.
END OF TREATMENT AND FOLLOW-UP
The patient will have a number of tests and procedures as part of follow up to treatment. These tests will be used to watch for improvements in tumor size, monitor for side effects from the treatment, evaluate how the T cells are working, and look for any signs that the cancer has come back. The patient's will have a physical exam and standard lab tests, including blood tests, and imaging studies about every 3 months during the first year after treatment.
|Study Type ICMJE||Interventional|
|Study Phase||Phase 2|
|Study Design ICMJE||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Condition ICMJE||Nasopharyngeal Carcinoma|
|Study Arms||Experimental: Chemotherapy and Immunotherapy
|Publications *||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Completion Date||July 2015|
|Primary Completion Date||June 2014 (Final data collection date for primary outcome measure)|
|Eligibility Criteria ICMJE||
|Ages||10 Years and older (Child, Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT00953420|
|Other Study ID Numbers ICMJE||25145-CADEN
CADEN ( Other Identifier: Baylor College of Medicine )
|Has Data Monitoring Committee||Yes|
|U.S. FDA-regulated Product||
|IPD Sharing Statement||Not Provided|
|Responsible Party||Chrystal Louis, Baylor College of Medicine|
|Study Sponsor ICMJE||Baylor College of Medicine|
|PRS Account||Baylor College of Medicine|
|Verification Date||August 2017|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP